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Mobilization of stem cells in acuteMImight signify the reparatory response. Aim of the Study. Prospective evaluation of correlation
between CD34+CXCR4+ cell mobilization and improvement of LVEF and remodeling in patients with acuteMI in 1-year followup.
Methods. 50 patients withMI, 28 with stable angina (SAP), and 20 individuals with no CAD (CTRL). CD34+CXCR4+ cells, SDF-1,
G-CSF, troponin I (TnI) and NT-proBNP were measured on admission and 1 year after MI. Echocardiography and ergospirometry
were carried out after 1 year. Results. Number of CD34+CXCR4+ cells in acute MI was significantly higher in comparison with
SAP and CTRL, but lower in patients with decreased LVEF ≤40%. In patients who had significant LVEF increase ≥5% in 1 year
FU the number of cells in acute MI was significantly higher versus patients with no LVEF improvement. Number of cells was posi-
tively correlated (r = 0, 41, P = 0, 031) with absolute LVEF change and inversely with absolute change of ESD and EDD in 1-year
FU. Mobilization of CD34+CXCR4+ cells in acute MI was negatively correlated with maximum TnI and NT-proBNP levels. Con-
clusion. Mobilization of CD34+CXCR4+ cells in acute MI shows significant positive correlation with improvement of LVEF after
1 year.
1. Background
Small numbers of bone-marrow (BM-) derived stem and
progenitor cells (SPC) are present in peripheral blood in hu-
mans. In acute coronary syndromes (ACS) and stroke the
number of circulating cells significantly increases. Such
mobilization of SPC is an inflammatory reaction, but the
presence of primitive SPC can also reflect the reparatory
mechanism. Mobilization of endothelial progenitor cells
(EPCs) reflects the turnover of vascular endothelial cells, be-
cause these cells contribute to endothelial renewal [1–3].
Myocardial infarction (MI) triggers the mobilization of not
only EPCs, but also other populations such as hematopoietic
stem cells (HSCs), mesenchymal stromal sells (MSCs), very
small embryonic like cells (VSELs) and other less well-
defined types [4, 5]. One of the populations that undergoes
rapid mobilization in acute MI are cells expressing chemo-
kine receptor CXCR4. These cells are enriched for early
markers of myocardial and endothelial differentiation and in
part also markers for primitive embryonic-like stem cells
(Oct-4, SSEA-4, Nanog) [5]. Our previous studies demon-
strated that in acute MI within several hours after the onset
of the chest pain there is a robust increase of CD34+CXCR4+
and CD34+CD117+ cells. The mobilization coexists with
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significant upregulation of cardiac (GATA-4, Nkx2.5/Csx,
MEF2C) and endothelial lineage markers (VE-cadherin, von
Willebrand factor), which suggests that these cells might con-
tribute to tissue repair following ischemic injury [4]. Mobil-
ization of BM-derived SPC is regulated by chemoattractants
released by ischemic myocardium, complement cascade, and
bioactive phospholipids [6].
In particular stromal-derived factor-1 (SDF-1)–CXCR4—
axis might contribute to homing of the SPC to the infarct
border area in the heart where it is expressed following MI.
This signaling axis is also the key factor regulating themobili-
zation of BM cells and renewal of hematopoiesis as well as in
inflammation [7]. Mobilization of BM by G-CSF is mediated
by disruption of SDF-1-CXCR4 binding [8]. Increased pro-
duction of SDF-1 via activation of hypoxia-inducible factor
1-α within the ischemic myocardium facilitates the homing
and engraftment of circulating BM cells which subsequently
participate in the reparatory processes [9].
Mobilization of SPC was investigated as a potential prog-
nostic marker in patients with stable coronary artery disease
(CAD) and the number of circulating EPCs correlated with
CAD risk factors, endothelium-dependent vasomotion, and
risk of ischemic events [10–12].
Prognostic value of measurement of SPC mobilization in
ACS is less well known. Acute MI triggers substantial inflam-
matory response which might affect the mobilization and
trafficking of stem cells. In addition, intensive treatment with
drugs known to affect the SPC release from the BM such
as statins and ACE-I might modulate to mobilization and
migration intensity. Other important factors are patients age
and comorbidities in particular diabetes [13]. There is a pau-
city of data on the association between mobilization of SPC
which might contribute to myocardial tissue repair and the
improvement of the left ventricle (LV) contractility and re-
modeling; however, pilot studies showed that in patients with
reduced LVEF in acute MI the mobilization of cells is less
efficient [14].
Improvement of LVEF following the primary percuta-
neous coronary intervention (pPCI) is a positive prognostic
factor for long-term survival in acute MI. Spontaneous
mobilization of SPC in acute MI is a form of reparatory
mechanism; therefore we conducted a prospective study to
evaluate the relationship of CD34+CXCR4+ cell mobiliza-
tion and long-term recovery of LV contractility, remodeling,
and clinical status (ergospirometry, NYHA, CCS class) in pa-
tients with acute MI in 1-year follow-up.
2. Patients andMethods
Study population consisted of 98 patients: 50 patients with
acute myocardial infarction (MI), 28 patients with stable
angina pectoris (SAP), and 20 individuals with no history of
ischemic heart disease (control group, CTRL). Subjects with
myocardial infarction were diagnosed according to the cur-
rent ST-elevation myocardial MI (STEMI) definition.
Inclusion criteria for patients with myocardial infarction
were
(1) time interval between the onset of chest pain and hos-
pital admission <12 hours,
(2) age < 75 years,
(3) patients qualified to pPCI.
Abciximab was administered in 64% of patients during
PCI procedure. All patients received unfractionated heparin
(70U/kg) to achieve ACT values >250. In all patients TIMI3
flow in the infarct-related artery was achieved. Statins (67%
simvastatin and 33% atorvastatin) were administered start-
ing from the first day of hospitalization.
Exclusion criteria were
(1) history of MI in the past,
(2) cardiogenic shock (IV class according to Killip-Kim-
ball scale),
(3) neoplastic disease,
(4) kidney and/or liver failure,
(5) coagulopathies and/or hematopoietic system diseas-
es,
(6) autoimmunological disorder and/or systemic inflam-
matory process,
(7) history of surgical procedure or coronary arteries per-
cutaneous intervention (revascularization) within
last 6 months.
Patients were diagnosed to have stable angina pectoris ac-
cording to the following: (a) typical clinical presentation/
symptoms (chest or arm discomfort/angina reproducibly
associated with physical exercise), (b) noninvasive test (posi-
tive exercise test/treadmill stress test) and qualified to plann-
ed coronarography. Presence of≥1 significant stenotic lesion
(≥70%) in coronary arteries was reported. Stable angina pec-
toris (SAP) and acute myocardial infarction (AMI) groups
were matched to avoid major differences in the context of
risk factors and pharmacological treatment which may affect
the number of cells circulating cells.
Control group (CTRL) individuals were diagnosed due
to valvular heart disease or rhythm disturbances.
The study protocol was approved by the Ethics Commit-
tee of the Medical University of Silesia and all patients signed
informed consent. The study conformed to the Declaration
of Helsinki and was funded by the European Union struc-
tural funds—Innovative Economy Operational Programme,
Grant POIG.01.01.02-00-109/09 “Innovative methods of
stem cells applications in medicine” and Polish Ministry of
Science and Higher Education Grants 0651/P01/2007/32,
2422/P01/2007/32 and statutory funds of Medical University
of Silesia.
2.1. Laboratory Measurements. Peripheral blood (PB) sam-
ples were collected within 12 hours of the first symptoms and
1 year after in patients with myocardial infarction, in SAP
and control group during routine clinical follow-up visit. 4–
6mL of PB was obtained from each patient and stored in
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both vacuum heparin tubes (2-3mL; measurement of pro-
genitor cell number) and vacuum EDTA tubes (2-3mL; mea-
surement of hematopoietic cytokines concentration).
The following parameters were measured:
(1) number of CD34+/CXCR4+ progenitor cells,
(2) concentration of chemoattractant factors (SDF-1, G-
CSF),
(3) troponin I (TnI) concentration and creatine kinase
MB isoenzyme (CK-MB) activity,
(4) NT-proBNP and high sensitive C-reactive protein
(hsCRP) concentration.
2.1.1. Measurement of CD34+CXCR4+ Cells. Blood samples
were transported in 4◦C to FACS facility processed within
4–6 hours after drawing. CD34+CXCR4+ cells number was
analyzed with FACS based on specific membrane antigens
expression in accordance to the ISHAGE criteria (Interna-
tional Society of Hematotherapy and Graft Engineering)
[15]. For isolation of mononuclear cells (MNCs) samples
were centrifuged through a Ficoll density gradient and sub-
sequently suspended in phosphate-buffered saline (PBS)
(1× 105/100 uL). Afterwards, MNCs were stained with flu-
orochrome-conjugated mouse monoclonal antibodies (Abs)
for the CD34 (phycoerythrin- (PE) conjugated Abs) and
CXCR4 (allophycocyanin- [APC-]conjugated Abs) and iso-
tope control (BD, Pharmingen, San Diego, CA, USA). Stain-
ing was performed at 4◦C for 30 minutes without light ex-
posure. Cells were subsequently washed twice in PBS, resus-
pended in 200 μL of PBS, and analyzed using a flow cyto-
meter (FACSCalibur, Becton Dickinson, San Jose, USA). At
least 106 events were acquired from each sample. The percen-
tage content of CD34+/CXCR4+ cells was calculated with ap-
propriate isotope control cut-offs. The absolute number of
(cells/μL) was calculated according to the previously publish-
ed method: CD34+/CXCR4+ percentage × leucocytes num-
ber/100 [14].
2.1.2. Chemoattractant and InflammatoryMarkers. Collected
PB samples were centrifugated (1000×g) at 4◦C for 15 min-
utes. Obtained plasma was stored at −30◦C. The centrifuga-
tion was performed within 30 minutes from blood sampling.
Additionally, for SDF-1 level measurement samples were
centrifuged (10 000×g) for 10 minutes in order to eliminate
platelets. Plasma levels of SDF-1, G-CSF, NT-proBNP, and
C-reactive protein were quantified using high sensitive kits
(G-CSF (Bender Medsystems); SDF-1 (Quantikine, R&D
systems); NT-proBNP (Quantikine, R&D systems), hsCRP
(Behring Nephelometer II Dade Behring)).
2.2. Echocardiography. Echocardiography was performed
after admission to hospital (<12 hours of chest pain symp-
toms) and 12 months post discharge during the follow-up
visit by experienced echocardiolographer. Transthoracic
echocardiography (M-mode and typical 2D projections) was
carried out in accordance to the American Society of Echo-
cardiography guidelines.
Evaluated echocardiography parameters were: left ventri-
cle end-diastolic (EDD) and end-systolic (ESD) diameter and
left ventricle ejection fraction (EF%) according to Simpson
method.
2.3. Ergospirometric Test. The test was performed 12 months
after myocardial infarction on the treadmill according to
modified Bruce protocol. The following parameters were
analyzed: resting heart rate (HRrest), peak heart rate
(HRpeak), maximum exercise time (Tmax), energy expendi-
ture in METs, maximal exertional oxygen uptake (VO2 peak)
presented as mL/kg/min and percentage of calculated norm
(VO2 peak %N), resting and peak ventilatory equivalent for
oxygen (VE/VO2 rest, VE/VO2 peak), peak/resting ventila-
tory equivalent for oxygen ratio (VE/VO2 peak/rest), resting
and peak ventilatory equivalent for carbon dioxide (VE/
VCO2 rest, VE/VCO2 peak), peak/resting ventilatory equiv-
alent for carbon dioxide ratio (VE/VCO2 peak/rest), ventila-
tion relative to carbon dioxide production (VE/VCO2 slope),
oxygen pulse and heart rate reserve (HRR)—according to the
American College of Sports Medicine guidelines and meth-
ods. Test was continued until limiting symptoms (fatigue,
chest pain, dyspnea) or lack of VO2 increase occurred. Test
was carried out on Oxycon Delta (Jaeger) system.
2.4. Clinical Status. Heart failure symptoms were evaluated
according to New York Heart Association (NYHA) classifica-
tion and angina severity according to Canadian Cardiovas-
cular Society (CCS) class.
2.5. Statistical Analysis. Number of SPC and levels of chemo-
attractants were expressed as median and interquartile range
(IQR). U Mann-Whitney and Wilcoxon tests were used for
comparison of time points and groups and Spearman rank
test for assessment of correlation. Logistic regression was
used to identify the factors associated with significant (2-
fold) mobilization of cells. Value of P < 0.05 was considered
significant. Statistica 6.0 PL for Windows package was used.
3. Results
Study groups (AMI and SAP patients) were comparable with
respect to risk factors profile, demographic data, and labora-
tory results excluding leucocyte number which was statis-
tically significantly higher in MI group. In comparison to
SA group patients with MI less frequently were on chronic
treatment with ASA (n = 31 (62%) versus n = 28 (100%),
P < 0.05). In MI group anterior MI was diagnosed in 30
(60%) andmultivessel coronary disease in 26 patients (52%).
In comparison of MI and SAP group with CTRL group the
following parameters were statistically significantly higher in
the study groups: mean age, percentage of patients with
hypertension, hypercholesterolemia, type 2 diabetesmellitus,
and family history of ischemic heart disease and smoking.
Clinical and demographic characteristics of the study pop-
ulation is shown are Table 1. 50 patients were followedup 1
year after MI. The medical treatment at the time of followup
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Figure 1: The number of circulating progenitor CD34+/CXCR4+
cells in peripheral blood. AMI: acute myocardial infarction, SAP:
stable angina pectoris, CTRL: control group, MI FU: 1-year follow-
up. Data is presented as cell number in 1 μL of peripheral blood
(median ± IQR). CD34+CXCR4+: CTRL 2,0 (0,2–3,4); SAP 2,1
(0,2–3,2); AMI 4,6 (0,4–8,9); MI FU 2,2 (0,2–4,0).
consisted of ASA (all patients), statin (n = 49), ACEI (n =
48), and beta-blockers (47 patients).
3.1.Mobilization of Stem/Progenitor Cells. The absolute num-
ber of CD34+CXCR4+ cells in patients with acute MI was
statistically significantly higher in comparison with SAP and
CTRL groups. In 1-year followup the number of circulating
CD34+CXCR4+ cells was similar in all three groups. There
were no statistically significant differences in cell number
between the control group and stable angina pectoris group
(Figure 1).
No differences in stem cell mobilization were noted in
subgroups of patients (males versus females (2,3 (0,3–8,95)
versus 2,1 (0,1–8,5); P = 0.99], presence of type 2 diabetes
[2,4 (0,1–7,6) versus 2,1 (0,1–8,9); P = 0.31). We found also
no significant differences in patients who were on chronic
treatment with statins [2,7 (0,4–7,9) versus 2,1 (0,4–7,9); P =
0, 84], ACE-I [2,1 (0,4–7,8) versus 2,4 (0,1–8,9); P = 0, 58].
3.2. Levels of Chemoattractants. In patients with acute MI
peripheral blood SDF-1 concentration was significantly low-
er than in SAP patients and healthy individuals. In 1-year fol-
low-up, there was no difference in plasma SDF-1 level among
three groups. No significant differences in SDF-1 concentra-
tion between CTRL and SAP group were observed (Table 2,
Figure 2).
In patients withMIG-CSF concentration was significant-
ly higher comparing to SAP and control group. No signifi-
cant differences in G-CSF concentration between CTRL and
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Figure 2: PlasmaSDF-1 levels. AMI: acute myocardial infarction,
SAP: stable angina pectoris, CTRL; control group, MI FUL: 1-year
followup. Data is presented as cell number in 1 μL of peripheral
blood (median ± IQR).
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Figure 3: Plasma G-CSF levels. AMI: acute myocardial infarction,
SAP: stable angina pectoris, CTRL: control group, MI FU: 1-year
followup. Data is presented as cell number in 1 μL of peripheral
blood (median ± IQR).
SAP group were observed. In 1-year followup, plasma G-CSF
level was similar in all three groups (Table 2, Figure 3).
In AMI study group there was significant positive corre-
lation between SDF-1 level and mobilized CD34+/CXCR4+
cells number (r = 0, 41, P = 0, 023). After 1 year, there was
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Table 1: Characteristics of the study group.
CTRL (n = 20) SAP (n = 28) AMI (n = 50) P
Age (years) (mean ± SD) 44,6 ± 6,2 56,7 ± 11,6 58 ± 11,5 P < 0.05 versus CTRL
Age (years) (median ± IQR) 44 (34–54) 56 (32–75) 57 (30–79) P < 0.05 versus CTRL
Male, n (%) 17 (57) 18 (60) 30 (60) P = NS
Hypertension, n (%) 7 (23) 17 (57) 30 (60) P < 0.05 versus CTRL
Hypercholesterolaemia, n (%) 8 (26) 23 (77) 35 (70) P < 0.05 versus CTRL
Type 2 diabetes mellitus, n (%) 0 11 (36) 18 (36) P < 0.05 versus CTRL
Smoking, n (%) 12 (40) 19 (63) 32 (64) P < 0.05 versus CTRL
Family history of IHD, n (%) 8 (27) 13 (43) 24 (48) P < 0.05 versus CTRL
Statins prior to hospitalization, n
(%)
0 20 (67) 32 (64) P < 0.05 versus CTRL
ACE inhibitors, n (%) 4 (13) 16 (53) 23 (46) P < 0.05 versus CTRL
Acetylsalicylic acid, n (%) 2 (7) 28 (100) 31 (62) P < 0.05 versus CTRL, SAP
Total cholesterol [mg/dL] 199 (156–256) 201 (156–256) 201,5 (122–313) P = NS
HDL cholesterol [mg/dL] 43 (20–70) 43 (24–75) 41 (13–74) P = NS
LDL Cholesterol [mg/dL] 97 (89–124) 100 (65–216) 105 (65–113) P = NS
Triglycerides [mg/dL] 150 (123–200) 176,5 (84–269) 163 (76–375) P = NS
Creatinine [mg/dL] 0,9 (0,7–1,4) 0,9 (0,8–1,3) 0,9 (0,7–14) P = NS
Erythrocytes [×106/μL] 4,7 (4,2–5,1) 4,7 (4,3–5,1) 4,62 (4,12–5,2) P = NS
Leucocytes [×103/μL] 6,9 (5,5–8,3) 6,6 (5,2–7,4) 10,17 ± 2,8 P < 0.001 versus CTRL,
SAP
Monocytes [×103/μL] 0,8 (0,4–1,2) 0,7 (0,46–1,14) 0,76 (0,41–1,1) P = NS
Platelets [×103/μL] 195 (143–246) 194 (137–251) 198 (146–250) P = NS
Initial LVEF ≤40%, n (%) — — 14 (28)
Initial CKMB [U/l] — — 26,5 (5–136)
Initial TnI [ng/mL] — — 0,7 (0,0–18)
Maximal CKMB [U/l] — — 109,5 (5–572)
Maximal TnI [ng/mL] — — 4,7 (0,92–72)
Anterior wall infarction, n (%) — — 30 (60)
Multivessel CAD, n (%) — — 26 (52)
Table 2
CTRL SAP AMI MI F-U (1 year)
SDF-1 [pg/mL] 3,2 (0,2–4,4) 2,9 (0,1–4,4) 1,8 (0,6–3,4) 3,0 (0,1–4,2)
P 0,77 versus CTRL
<0.0001 versus CTRL
<0,0001 versus SA
0,81 versus CTRL
0,92 versus SA
<0,0001 versus MI
G-CSF [pg/mL] 27 (0,7–66) 25 (0,1–50) 74 (6–141) 30 (0,8–71)
P 0,78 versus CTRL
<0,0001 versus CTRL
<0,0001 versus SA
0,9 versus CTRL
0,83 versus SA
<0,0001 versus MI
no significant correlation between levels of SDF-1 and G-
CSF and number of circulating cells. We found no differences
in SDF-1 and G-CSF levels in subgroups of patients (males
versus females, presence of type 2 diabetes, and chronic
treatment with statins). In patients with MI older than 50
years the number of mobilized CD34+CXCR4+ cells and
plasma SDF-1 level were significantly lower than in younger
patients. CD34+/CXCR4+ cells number: 2,8 (0,4–4,95) ver-
sus 5,7 (3,8–8,95); P < 0.0001 for patients ≥ and <50 years,
respectively. SDF-1 level: 1,5 (0,6–2,4) versus 2,7 (1,4–3,4);
P = 0.004 for patients ≥ and <50 years, respectively.
Plasma SDF-1 concentration was a single, independent
prognostic factor of significant progenitor cells mobilization
[Odds ratio (95% confidence interval): OR 5,8 (95% CI: 5–
22); P = 0, 01].
3.3. Left Ventricle Contractility and Remodeling. 50 patients
with acute MI were evaluated by echocardiography in order
to determine the correlation between circulating progenitor
cell number and LVEF and remodeling (ESD, EDD). Initial
echocardiographic examination revealed LVEF impairment
(≤40%) in 14 individuals (28% of MI patients). Significant
LVEF improvement (≥5%) during the follow-up was observ-
ed in 19 patients (38%). In 1-year observation, decreased
LVEF ≤40% was diagnosed in 19 patients (38%). There were
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Figure 4: Circulating CD34+CXCR4+ cells in the acute phase ofMI
in patients with LVEF >40% versus ≤40%.
no significant differences between median EDD and ESD
values measured 12 months after MI and during the acute
phase as shown in Table 3. Also no differences in terms of
medical treatment between patients with and without recov-
ery of LVEF were found.
3.4. Mobilization of the Stem and Progenitor Cells in Rela-
tion to LVEF and Remodeling. The absolute numbers of
CD34+CXCR4+ cells in acute MI was significantly lower in
patients with decreased left ventricle ejection fraction (LVEF
≤ 40%) in the acute phase of MI [2,0 (0,4–7,8) versus 4,7
(0,7–8,9); P = 0, 028], as well as in 1-year followup [2,3 (0,3–
5,8) versus 5,5 (2,8–8,9); P < 0.0001] (Figures 4 and 5).
There was a significant positive correlation between
CD34+CXCR4+ cells mobilization and left ventricle ejection
fraction in first 24 hours after myocardial infarction (r =
0, 39, P = 0, 03) (Figure 6).
In control echocardiographic evaluation it was shown
that CD34+CXCR4+ cells number in acute MI was positively
correlated with LVEF 12 months after MI (data not shown).
There was significant positive correlation (r = 0, 41, P =
0, 031) between the number of mobilized progenitor cells in
the acute phase of myocardial infarction and LVEF change in
12-month observation (ΔLVEF; F-U) (Figure 7).
Additionally, it was shown that in patients who had LVEF
increase≥5% in 12-month observation the number of circu-
lating cells in the acute phase of myocardial infarction was
significantly higher comparing to patients with decreased
LVEF, no LVEF change and insignificant LVEF improvement
[6,8 (1,9–8,9) versus 3,7 (0,4–6,8); P < 0, 0001] (Figure 8).
Multivariate logistic regression analysis included param-
eters which were predictors of changes of LVEF over 1 year in
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Figure 5: Mobilization of CD34+CXCR4+ cells in acute MI in
patients who had preserved or reduced LVEF at 1-year followup post
MI.
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Figure 6: Correlation between CD34+CXCR4+ cells mobilization
and initial LVEF value in patients with MI.
univariate model (peak values of TnI, peak activity of CK-
MB, anterior localization of MI, time to reperfusion, and
number of circulating CD34+CXCR4+ cells in acute MI).
Only anterior localization of MI and peak values of TnI, but
not number of circulating cells, were independent predictors
of LVEF changes over time.
There was a significant negative correlation between
mobilization of CD34+CXCR4+ cells in acute MI with ESD
and EDD in the acute phase of MI as well as after 1 year (data
not shown). The number of mobilized CD34+CXCR4+ cells
in acute MI was inversely correlated with absolute change of
ESD and EDD (Figure 9).
In MI patients with LVEF below 40% the SDF-1 levels
were lower than in patients with preserved LVEF [1,45
(0,6–2,9) versus 2,0 (0,9–3,45) pg/mL; P = 0.008] (data
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Table 3: Left ventricle ejection fraction and remodeling in 1-year follow-up in patients with MI.
Parameter Acute MI 1 year FU P value
LVEF (%) 44,7 ±10,2 45,9 ± 10,5 0,17
EDD (mm) 51,6 ± 5,5 51,1 ± 5,5 0,9
ESD (mm) 33,4,6 ± 3,9 35,1 ± 5,1 0,08
ΔLVEF (%) — 1,2 ± 6,7 —
ΔESD (mm) — 2,5 ± 3,3 —
ΔEDD (mm) — 0,5 ± 2,9 —
25
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Figure 7: Correlation between peripheral blood CD34+/CXCR4+
progenitor cells number and the absolute LVEF change 12 months
post MI.
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Figure 8: Comparison of CD34+/CXCR4+ progenitor cells mobi-
lization in the acute phase of myocardial infarction in patients with
the absolute LVEF improvement ≥5% (Δ ≥ 5%); 12-month clinical
followup.
not shown). There were no significant correlations between
chemoattractants and LVEF and LV remodeling after 1 year.
Mobilization of CD34+CXCR4+ cells measured in acute
MI was negatively correlated with maximum TnI levels
(Figure 10).
NT-proBNP levels in patients with acute MI were signi-
ficantly higher than in SA group [170 (34–860) versus 80
(23–167) pg/mL; P < 0, 0001]. Number of circulating cells in
acute MI was significantly negatively correlated with plasma
NT-proBNP levels (r = −0, 48, P = 0.03). In patients
with MI, high sensitive C-reactive protein (hsCRP) level was
statistically significantly increased. In 1 year follow-up, the
hsCRP level were similar in all three groups (Figure 11).
There were no significant correlations between hsCRP
levels and mobilization of CD34+CXCR4+ in acute MI (r =
−0.17, P = 0.22).
3.5. Ergospirometry and Functional Status. The ergospirome-
try test was carried out in 48 of 50 patients after 1 year after
MI. Results are shown in Table 4.
Only variable that correlated with mobilization of
CD34+CXCR4+ cells was VO2 peak (r = 0.34, P = 0.01).
Similarly, there were no differences in number of circulating
cells and chemoattractants in patients stratified according to
NYHA class at 1-year followup.
4. Discussion
Acute MI triggers the release into peripheral blood of BM-
derived stem and progenitor cells, such as EPCs, VSELs,
HSCs, andMSCs. In present study we provided evidence that
mobilization of CD34+CXCR4+ cells in acute MI was signif-
icantly correlated with improvement of LVEF and LV re-
modeling in 1-year followup. Reduced mobilization of
CD34+CXCR4+ cells in acute phase of MI was associated
with more significant impairment of LVEF and greater
infarct size measured as the release of TnI. We evaluated the
mobilization of CD34+CXCR4+ cells in acuteMI in compar-
ison to patients with stable angina and control group without
CAD. According to our previously published results the
maximum mobilization of cells occurred early within 12
hours after the onset of ischemia and the number of circu-
lating cells increased approximately 2.3-fold. The number of
these circulating cells after 1 year was comparable to patients
with stable CAD and healthy subjects. Mobilization of the
stem and progenitor cells might therefore be considered a
part of an inflammatory response in response to myocardial
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Figure 9: Correlation of CD34+CXCR4+ progenitor cell number in the acute phase of MI with the absolute EDD change (ΔEDD) and ESD
(ΔESD) in 12-month clinical observation.
Table 4: Results of ergospirometry.
VO2 peak VE/VCO2 slope VE/VCO2 peak/rest VE/VCO2 peak VE/VCO2 rest
Median (Range) 26.0 (13–33) 29.7 (18,1–41,6) 0.88 (0,68–0,99) 33.13 (24–50) 42.98 (30–51)
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Figure 10: Correlation between CD34+CXCR4+ cells mobilization
in the acute phase of MI and maximum levels of troponin I.
ischemia and necrosis. Current observations are consistent
with other studies investigating mobilization of EPCs and
HSCs which showed rapid release of cells. Therefore mea-
surement of CD34+CXCR4+ cells at admission reflects in
our opinion the maximum mobilization triggered by acute
MI [3–5].
Our previous studies demonstrated that CD34+CXCR4+
and c-met+ cells are present in increased numbers for
first 2-3 days and is gradually reduced within a week [4].
Accordingly Leone et al. showed that in acute MI sev-
eral populations of cells CD34+CD33+, CD34+CD38+,
CD34+CD117+, and CD34+VEGFR2+ are mobilized within
6 hours after the onset of ischemia and returned to levels
comparable with stable CAD within 2 months [17]. Leone
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Figure 11: Plasma hsCRP levels. Patients: with acute myocardial
infarction: AMI, with stable angina pectoris: SAP, control group:
CTRL, 1-year followup: MI FU. P = 0, 47 SAP versus CTRL; P <
0, 0001 AMI versus CTRL; P < 0, 0001 AMI versus SAP; P = 0, 21
MI F-U versus CTRL; P = 0, 73 MI FU versus SAP; P < 0, 0001 MI
F-U versus AMI.
et al. also confirmed the rapid release of cells within 24 hours
afterMI [17]. Conversely, Shintani et al. showed that the peak
number of CD34+ cells occurred later, about 7 days after
the onset of ischemia [3]. Mobilization of BM cells was
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confirmed also in non-ST-segment elevation acute coronary
syndromes [13].
So far there was no prospective study which investigated
the relations between mobilization of BM cells and recovery
of LV contractility following acute MI. In the present study
we showed that the mobilization of CD34+CXCR4+ cells is
positively correlated with LVEF both measured in the acute
phase as well as its recovery over 1-year followup. We also
showed that almost 30% of patients had reduced LVEF
≤40% and these patients had significantly less circulating
cells than patients with preserved LVEF. Reduced mobiliza-
tion was also observed in patients with no significant im-
provement of LVEF following reperfusion over the long-
term followup. Patients with a significant increase of LVEF
defined as increase ≥5% had significantly higher number
of circulating cells. In addition our study suggests that the
release of CD34+CXCR4+ cells is inversely correlated with
LV remodeling measured by absolute increase of EDD and
ESD over 1 year. Overall the findings show consistently
that in patients with reduced LVEF and lack of significant
improvement of contractility as well as more significant re-
modeling the mobilization of CD34+CXCR4+ cells in acute
MI is reduced.
There is a paucity of data on such associations in the
literature. Leone et al. assessed the correlation of CD34+with
LVEF in 54 patients with acute MI. Number of cells was mea-
sured after 1 year. Authors showed that mobilization of
CD34+ cells was an independent predictor of improvement
of LVEF and it was positively correlated with absolute in-
crease of LVEF and negatively with wall motion score index
(WMSI) and end-systolic volume. Patients with most signi-
ficant improvement of LVEF as well as a reduction of WMSI
and LV volumes had also higher number of circulating
CD34+ cells 1 year after MI [16]. In this study however only
16 patients were treated with primary PCI and 12 had no
reperfusion treatment at all. Also only 45% of cells were
CXCR4+, so this study evaluated different population of BM
cells [17]. Conversely Massa et al. showed no correlation
between EPCs, HSCs, and LVEF in patients with acute MI
[18]. In the present study we enrolled only patients treated
with primary PCI and final TIMI3 flow to reduce the bias
caused by inclusion of patients without proper reperfusion
which translates into LV remodeling. We did not find any
differences in mobilization of cells in subgroups of patients
stratified by sex, presence of diabetes, hypertension, and obe-
sity. Interestingly we observed that the mobilization was
lower in older patients in comparison to those younger than
50 years. Proper interpretation of the results requires the con-
sideration of other factors that can modulate the process
of mobilization, including age, medications, and profile of
CAD risk factors. Generally the mobilization and function
of circulating SPC is reduced in elderly and diabetes. On
the other hand statins improve the mobilization, viability,
and function of these cells; however most available data re-
ferred to EPCs. Our population of cells was distinct from
EPCs and definitely more heterogenous. On the other hand
subpopulation of CXCR4+ cells (CD133+CXCR4+VSELs) is
indeed reduced in diabetic patients with acute MI [5, 13].
The presence of correlations between LV contractility,
remodeling, and mobilization of cells which theoretically
might contribute to tissue repair is clearly not a proof of
a causal relationship but only a hypothesis-generating con-
cept. We hypothesized that some populations of BM cells
might be particularly intriguing because of their ability to ex-
press early cardiac and endothelial lineage markers which
suggest they might play a role in cardiac reparatory reaction
following MI. We previously showed that some populations
of circulating cells (CD34+CXR4+, VSELS) express mRNA
for early cardiac (Nkx2.5/Csx, GATA-4)muscle and endothe-
lial markers (VE-cadherin, von Willebrand factor). The
increased expression of these markers is in temporal correla-
tion with maximum mobilization of CXCR4+ cells [4].
We also demonstrated that acute MI triggers mobilization
of VSELs expressing early developmental markers (Oct-4,
Nanog, SSEA-4). On the other hand, murine VSELS show-
ed potential for differentiation into cardiac myocytes [6]. It
seems that mobilization of CXCR4+ cells reflects not only
an inflammatory reaction following MI, but is also a part
of repair mechanism. Interestingly the potential for differen-
tiation of circulating progenitor cells was shown to be cor-
related with improvement of LVEF after MI as shown by
Numaguchi et al. [18]. In our study the levels of chemoat-
tractants (SDF-1, G-CSF) were not significantly correlated
with improvement of LVEF or remodeling. Release of TnI in
acute MI is strongly correlated with the infarction size and
is a predictor of LVEF recovery following MI. Other impor-
tant predictors are anterior localization and time from the
onset of symptoms to reperfusion [16]. In our hands the
mobilization of CD34+CXCR4+ cells was inversely corre-
lated to maximum levels of TnI and activity of CK-MB,
which suggests that patients with blunted mobilization of
stem cells developed larger infarcts. This might in part ex-
plain reduced LVEF recovery and increased remodeling in
this group. Massa as well as Leone et al. however found no
association between circulating cells and myocardial necrosis
markers [5, 16, 17]. In addition Voo et al. showed that num-
ber of EPCs is positively correlated with myocardial necrosis
and levels of CRP [19]. In multivariate analysis however the
number of CD34+CXCR4+ cells was not an independent
predictor of LVEF recovery.
We investigated if the mobilization of BM cells is related
to functional status of the patients in 1-year follow-up. We
showed no differences between patients presenting with MI
with or without heart failure (Killip-Kimball class). In the
long-term follow-up we used cardiopulmonary exercise test
which is a noninvasive, reproducible, and reliable tool for
evaluation of exercise tolerance. Such study was completed
by 96% of patients. The only parameter which showed a
positive correlation with the number of circulating cells mea-
sured 1 year after MI was VO2 peak. It seems that improved
LVEF and less remodeling in patients with a higher number
of circulating cells might have translated into better exercise
capacity. NT-proBNP is a significant prognostic marker in
acute coronary syndromes and heart failure [21]. We found
increased levels of NT-proBNP in patients with MI which
were inversely correlated with LVEF, but also with the num-
ber of circulating CD34+CXCR4+ cells. Valgimigli et al.
10 Mediators of Inflammation
showed that number of circulating CD34+CD45+ cells and
EPCs in patients with chronic heart failure is reduced in
higher NYHA class, inversely correlated with BNP and posi-
tively with peak VO2 in ergospirometry [21]. We found no
evidence of correlation between cell mobilization, chemoat-
tractants levels with NYHA and CCS class in 1-year followup.
Several other studies showed that in patients with heart
failure the numbers of circulating stem and progenitor cells
as well as their functional capacity are reduced [15, 22].
Mobilization and homing of circulating stem and pro-
genitor cells is regulated by expression of chemoattractants,
such as chemokines (SDF-1), growth factors (VEGF) or cyto-
kines (G-CSF) as well as activation of the complement cas-
cade and bioactive phospholipids.
Several chemoattractants, such as SDF-1, LIF, and HGF,
are expressed in the myocardium in particular in infarct bor-
der-zone. This suggests that cells with receptors for chemoat-
tractant are preferentially taken up in these areas [22, 23].
Our study showed increased levels of G-CSF and decrease in
SDF-1 levels in acute MI. Previously we demonstrated that
following MI the baseline low levels of SDF-1 increase over
time, which corresponds with peak expression of SDF-1 in
the myocardium which occurred later than mobilization of
CXCR4+ cells [7]. SDF-1 levels are predictors of significant
mobilization of CD34+ cells [4]. Probably for stem cell hom-
ing the local expression of SDF-1 in the heart is more impor-
tant than blood levels which show high individual varia-
bility. We found however no significant correlations between
plasma G-CSF levels and cell mobilization as well as any of
the clinical parameters. Similarly there were no significant
correlations between increased levels of hsCRP in patients
with acute MI and cell mobilization.
The limitations of the study are relatively small sample
size and use of echocardiography instead ofMRI in particular
in the analysis of comparison between patients with and
without significant (>5%) improvement of LVEF. Addition-
ally, we compared the release of SPC in acute MI to number
of cells in patients with stable CAD and control subjects
without CAD. Latter two groups were different in regard to
age and use of medications from patients with MI, so we
could not have excluded the bias, because both factors modu-
late the number of circulating cells.
4.1. Summary. Mobilization of CD34+CXCR4+ cells in
acute MI shows significant positive correlation with left ven-
tricular ejection fraction and inverse correlation with infarct
size and NT-proBNP levels. Number of circulating cells is
lower in patients with reduced LVEF, LV remodeling and
those without significant improvement of LV contractility in
1-year follow-up.
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